Abnormal radioiodine uptake on post-therapy whole body scan and sodium/iodine symporter expression in a dermoid cyst of the ovary: report of a case and review of the literature

Alfredo Campennì1, Salvatore Giovinazzo2, Giovanni Tuccari3, Simone Fogliani4, Rosaria M. Ruggeri2, Sergio Baldari1

SUMMARY
In patients affected by differentiated thyroid cancer, the whole-body scan (WBS) with 131I-radioiodine, especially when performed after a therapeutic activity of 131I, represents a sensitive procedure for detecting thyroid remnant and/or metastatic disease. Nevertheless, a wide spectrum of potentially pitfalls has been reported. Herein we describe a 63-year-old woman affected by follicular thyroid cancer, who was accidentally found to have an abdominal mass at post-dose WBS (pWBS). pWBS showed abnormal radioiodine uptake in the upper mediastinum, consistent with lymph-node metastases, and a slight radioiodine uptake in an abdominal focal area. Computed tomography revealed an inhomogeneous mass in the pelvis, previously unrecognized. The lesion, surgically removed, was found to be a typical dermoid cyst of the ovary, without any evidence of thyroid tissue. By immunohistochemistry, a moderate expression of the sodium-iodine symporter (NIS) was demonstrated in the epithelial cells, suggesting a NIS-dependent uptake of radioiodine by the cyst. Arch Endocrinol Metab. 2015;59(4):360-3

INTRODUCTION
Differentiated thyroid cancer (DTC), accounting for about 90% of all thyroid cancers, represents the most common endocrine malignancy and its incidence has increased in worldwide population (1). The initial treatment for DTC patients is total or near-total thyroidectomy, with or without lymph nodes dissection (2,3). Radioiodine aid the management of DTC patients who have undergone surgical treatment, and its role in the diagnosis and treatment of such patients is well established (2,3). Whole-body scan (WBS) with radioiodine, especially when performed after a therapeutic activity of 131I, represents an important diagnostic tool, in particular in intermediate or high risk DTC patients (2-4). Indeed, post-therapy WBS (pWBS) is a highly sensitive procedure for detecting residual normal thyroid tissue as well as metastases in local lymph nodes or distant sites (2-4). Nevertheless, false-positive scans, showing the presence of 131I uptake in the absence of residual thyroid tissue or metastases can occur in different situations. Beside healthy tissues (i.e. salivary glands, breast, liver, and gastrointestinal tract), unexpected radioiodine uptake have been seen in benign diseases, such as cysts and inflammation, as well as in benign and malignant non-thyroidal tumors, which could be mistaken for metastases (5). Several potential pitfalls in the interpretation of WBS have been reported in the literature (5). Some of them are relatively common (6), while others are very uncommon in our experience (7-9). Herein we describe a case of 131I accumulation in an ovarian dermoid cyst accidentally discovered at pWBS in a DTC patient.

CASE REPORT
A 63-year-old woman underwent near-total thyroidectomy for a large multi-nodular goiter. Histopatho-
logical reports revealed a follicular thyroid carcinoma with minimal vascular invasion (pT3, N0, Mx). After conventional L-T4 withdrawal, the patient underwent radioiodine thyroid uptake (RTU) measurement, 24 hours after oral administration of 131I tracer activity (1.8 MBq), followed by radioiodine therapy (RIT) with ablative activity (3700 MBq). A post-dose 131I whole body scan (pWBS) was performed five days after RIT, using dual-headed gamma camera equipped with high-energy low-resolution parallel-hole collimator (HELRPAR). pWBS showed abnormal and intense radioiodine uptake in the upper mediastinum, consistent with lymph-node metastases (Figure 1, panels A and B, and a slight radioiodine uptake in an abdominal focal area located on the bladder activity (Figure 1, panels A and B, white arrow). At the time of RIT, serum TSH and Tg were 39.5 UI/mL and 546 ng/mL respectively. In absence of TgAb, Tg levels were consistent with the presence of metastases. Computed Tomography (CT), performed before and after medium contrast administration, revealed a bilobed, inhomogeneous mass in the median region of the pelvis, extending to the upper wall of the bladder (Figure 1, panels C and D, white arrow). Our patient was unaware of this lesion and asymptomatic. A few weeks later, patient underwent surgical exploration with complete excision of the mass. Pathological examination was conclusive for a typical dermoid cyst of the ovary. No normal or tumoral thyroid tissue could be found in the context of the cystic lesion. A moderate expression of the sodium-iodine symporter (NIS) was demonstrated in the epithelial cells lining the cystic cavity, by immunohistochemistry (anti-NIS antibody SLC6A3, MyBioSource.Com, San Diego, CA, USA; working dilution, 1:25) (Figure 2). Immunostaining for hTg was negative, thus confirming the absence of thyroid tissue in the context of the dermoid cyst, as per gross pathology evaluation.

A few months later, the patient underwent a second RIT by administration of 131I therapeutic activity (5550 MBq) in hypothyroid state (after five weeks of L-T4 withdrawal). pWBS confirmed lymph-node metastases in the mediastinum (Figure 3, black arrow), but did not reveal any radioiodine uptake in abdomen, confirming that radioiodine uptake was only caused by the dermoid cyst. At the time of the second RIT, serum TSH and Tg were 112 UI/mL and 242 ng/mL, respectively. TgAb were negative.

**DISCUSSION**

In patients affected by DTC, the post-therapy 131I WBS represents a sensitive procedure for detecting thyroid remnant and/or metastatic disease (2-4). Nevertheless, a wide spectrum of potentially misleading readings has been reported following its use (5).

Multiple different false-positive localizations of 131I has been described in the absence of residual thyroid tissue or metastases from DTC (5-9). The underlying mechanisms of such unusual localizations are not always fully understood. In many cases, the iodine uptake may be due to the expression of the sodium/iodine symporter (NIS) in ectopic thyroid tissue as...
Radioidine uptake in a dermoid cyst of the ovary

Figure 3. Panels A (anterior view) and B (posterior view). 131I whole body scan confirmed abnormal radioiodine uptake in the upper mediastinum (black arrow), but did not confirm abdominal radioiodine uptake.

well as in non-thyroidal normal or pathological tissues (5,10-12). In some instances, foci of 131I activity are not related to the presence of NIS, but due to retention of radioiodine in physiologic body fluids accumulated in ducts or cavities (13,14) as well as contamination by physiologic secretions (5). In addition, it has also reported radioiodine trapping in various inflamed tissues and/or cysts because of their increased vascularity and capillary permeability (15-17). Finally, in some cases, the mechanism for 131I trapping remains unknown. Unless recognized as a false positive, 131I uptake may result in diagnostic error and lead to unnecessary 131I therapy or surgical procedures.

Here we report an unexpected and potentially misleading 131I uptake in the abdomen, revealed at the pWBS, in a DTC patient. The CT scan showed the presence of a bilobed, inhomogeneous mass in the median region of the pelvis. The lesion, previously unrecognized and asymptomatic, was surgically removed, and it was found to be a typical dermoid cyst of the ovary, without any evidence of thyroid tissue nor tumour cells.

Dermoid cysts, also known as teratomas, are germ cells tumours, histologically composed of mature tissues that develop from ectoderm, mesoderm and/or endoderm. Typical dermoid cysts are epithelial-lined cavities with skin appendages, including hair, hair follicles, sebaceous material, deriving from ectodermal tissue. They may also contain mesodermal tissue (bone, teeth...), and tissue of endodermal origin, including well differentiated thyroid tissue (18). Dermoid cysts primarily occur in the gonads, mostly in female patients. However, dermoids are not unique to a single anatomic location, but may occur anywhere in the body. Moreover, they are often clinically silent, so that the patient is unaware of this malformation, as in our case.

Ovarian radioiodine uptake at radioiodine WBS, although so uncommon, has been previously reported (19). However, it usually occurs in germ line tumours which contain well-differentiated thyroid tissue and just because they contain it. As shown in the literature (18), up to 20% of ovarian teratomas contain thyroid tissue, and 5% of them are struma ovarii, defined as the tumour being more than half thyroid tissue (18,19). Struma ovarii represent an uncommon but well known false-positive localization of 131I (20-22), because it is mainly or exclusively composed of well-differentiated and functioning thyroid tissue, able to trap iodine as well as to produce thyroid hormones and thyroglobulin (18-22). Up to date, there are only four reports in the literature of radioiodine uptake by ovarian dermoid cysts, not be classified as struma ovarii (23-26).

Rudoni and cols. first reported on a 44-year old woman who underwent total thyroidectomy for a papillary cancer. The pWBS demonstrated a focal uptake in the pelvis, that was found to be due to a typical dermoid cyst of the ovary (23). After this first report, three other cases were described (24-26). All were childbearing-age female patients, who have been previously undergone total thyroidectomy for DTC, two papillary and one follicular cancer. In all patients, as in our, the ovarian lesion was clinically silent and previously unrecognized, and it was incidentally discovered on WBS in the follow-up of the thyroid cancer. The WBS showed an abnormal pelvic uptake, associated with an elevated Tg value just in one patient (26). Thus, the patients underwent further imaging evaluation (CT or magnetic resonance imaging), showing an ovarian lesion, followed by the surgical removal of the mass. The histological examination was always conclusive for a benign dermoid cyst (not struma ovarii). In all except one (23) of these cases, the lesion contained a variable amount of benign, well-differentiated thyroid tissue, thus justi-
fying the radioiodine uptake. Prior of us, just Rudoni and cols. reported $^{131}I$ uptake in a ovarian dermoid cyst, that was totally devoid of thyroid tissue at histological diagnosis, as in our case, but the Authors did not provide any possible explanation of such unusual finding (23). We first demonstrated the expression of NIS in the epithelial cells of the cystic lesion, suggesting that radioiodine uptake was NIS-dependent, and not related to the increase of vascularity or capillary permeability.

In conclusion, we describe a very uncommon case of false positive ovarian uptake of radioiodine in a WBS for DTC, due to a typical dermoid cyst expressing the NIS on its epithelial cells. Due to the non-negligible frequency of this malformation, dermoids should be taken into account in DTC patients as a potential pitfall at $^{131}I$-WBS.

Statement of authorship: each author gave a substantial contribution to the paper and approved the final version to be published.

Funding statement/competing interest: this work was not supported by any grant.

Disclosure: no potential conflict of interest relevant to this article was reported.

REFERENCES


